Aviceda Therapeutics
Manufacturing · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1 Broadway Ste 14, Cambridge, Massachuse...Phone Number
(617) 225-4343Website
www.avicedarx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Aviceda Therapeutics
Aviceda Therapeutics, headquartered in Cambridge, Massachusetts, is a company that develops next-generation immuno-modulators from glyco-immunology.Explore more
Aviceda Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Aviceda Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Aviceda Therapeutics is spiking on competitors!
Check if Aviceda Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Aviceda Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Aviceda Therapeutics launches new products
Aviceda Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Click to see if Aviceda Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on Aviceda Therapeutics recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Aviceda Therapeutics
Recommended Actions
Reach out to Masked Content who joined Aviceda Therapeutics as Masked Content
Find more new buyers
Compare Similar Companies to Aviceda Therapeutics
Compare insights from companies similar to Aviceda Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Aviceda Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Aviceda Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Aviceda Therapeutics.
Aviceda Therapeutics financials insights
Gather financial insights about Aviceda Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$4.3M
2021
Debt
$1.9M
2025
Series C
$207.5M
Aviceda Therapeutics Tech Stack
A closer look at the technologies used by Aviceda Therapeutics
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
Funding
Funding
Open Position
Open Position
Open Position
Aviceda Therapeutics News & Media
Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Directors
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of DirectorsAviceda Therapeutics Appoints Industry Veteran Dr. Jeffrey Nau as Chief Executive Officer to Lead Next Phase of Growth and Innovation
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aviceda Therapeutics Appoints Industry Veteran Dr. Jeffrey Nau as Chief Executive Officer to Lead Next Phase of Growth and InnovationAviceda Therapeutics Raises Upsized $207.5 Million in Series C Financing Round to Advance Lead Program AVD-104 for Geographic Atrophy into Pivotal Trials
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aviceda Therapeutics Raises Upsized $207.5 Million in Series C Financing RoundAviceda Therapeutics Completes Enrollment of Phase 2b SIGLEC Study Assessing the Safety and Efficacy of AVD-104 for Geographic Atrophy Secondary to AMD
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aviceda Therapeutics, a private, clinical-stage biotech company focused on developing next-generation immunomodulators with a proprietary HALOS™ nanotechnology platform to alleviate chronic, non-resolving inflammation, announced today that the company completed enrollment of the Phase 2b SIGLEC study that compares the safety and efficacy of AVD-104 versus avacincaptad pegol (Izervay) in patients with geographic atrophy (GA) secondary to age-related macular deg
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Aviceda Therapeutics
Sign Up For FreeTo access detailed company insights
Aviceda Therapeutics, headquartered in Cambridge, Massachusetts, is a company that develops next-generation immuno-modulators from glyco-immunology.... Read More
